News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The company will market it under the brand name Molflu
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Subscribe To Our Newsletter & Stay Updated
